- |||||||||| ceftriaxone / Generic mfg.
Initial Presentation of MOGAD Masquerading as Acute Para-infectious Flaccid Myelitis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3309;
This case illustrates that CSF findings in patients with transverse myelitis due to MOGAD can demonstrate marked pleocytosis and elevated protein in the acute phase - similar to findings expected in infectious flaccid myelitis. The possibility that infections trigger MOGAD remains under investigation, though some case series demonstrate EBV, HSV and Influenza as possible triggers of MOGAD encephalomyelitis 3,4.
- |||||||||| Avastin (bevacizumab) / Roche
Brainstem Gliomatosis Cerebri Presenting as a Cerebellopontine Angle Tumor (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3243;
Typical signs and symptoms are nonspecific, such as seizure, headache, cognitive decline, and focal motor deficits, making them challenging to identify (Georgakis, Tsivgoulis, & Spinos, 2018). Our patient presented with symptoms mimicking a cerebellopontine angle lesion.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Atypical Pharyngo-Cervico-Brachial Variant of GBS Associated with Covid-19 Antibodies (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3090;
She was tested for total Covid-19 antibodies which was significantly positive with 55.25 COI. Patient was treated initially with IV Methylprednisolone with no significant response. Atypical Pharyngo-cervico-brachial variant of GB Syndrome with gross asymmetrical upper limb weakness and progressed over six weeks associated with positive SARS Cov-2 antibodies. During the pandemic, unusual neurological manifestations should be evaluated for possibility of SARS-CoV-2 associated antibodies as neuropathogenesis has shown both vascular and post infectious demyelinating disorders.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab Associated Myasthenia Gravis and Myocarditis Associated with Anti-striational Antibody (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2952;
Background: We report a case with successful outcome of pembrolizumab associated anti-striational antibody myasthenia gravis (MG) after being treated aggressively with methylprednisolone, Intravenous immunoglobulin (IVIG) and plasmapheresis (PLEX). Early aggressive treatment with IVIG or PLEX and steroids, regardless of initial symptoms severity, may lead to better outcomes in patients presenting with pembrolizumab associated anti-striational antibody MG.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Co-Occurrence of Sj/ITPR1 and NMDA Antibodies: A Case Report (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2924;
Given the rarity of cerebellar ataxia in anti-NMDA encephalitis in adults, one could argue for a pathogenic role of ITPR1 in our case. No underlying malignancy was identified in our patient.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Longitudinal Myelitis as a COVID-19 Neurological Manifestation (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2878;
No underlying malignancy was identified in our patient. This unique case of a longitudinal myelitis in the setting of SARS-CoV-2 infection adds to previously reported cases of acute disseminated encephalomyelitis, meningoencephalitis, and optic neuritis as neurological manifestations of SARS-CoV-2 infections [2].
- |||||||||| dexamethasone / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
Fluoroscopy Guided Block in Nervus Intermedius Neuralgia (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2864;
Due to its rarity, there is inconclusive evidence for treatment guidelines. Current treatment includes carbamazepine, gabapentin, baclofen or neurosurgical procedures if medication fails.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Acute Transverse Myelitis: an upcoming complication of COVID-19 infection (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2660;
Most patients with ATM presented with a long latency period (beyond 2 weeks after the initial COVID-19 positive test) and intravenous steroid therapy helps, but most patients seem to require additional IVIg or plasma exchange before showing clinical improvement. We encourage further large scale studies in this regard.
- |||||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Atypical Optic Neuritis Associated with golimumab (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2638;
Our case not only provides evidence of severe atypical optic neuritis associated with golimumab in a patient with a prior episode of undiagnosed CNS demyelination. Furthermore, our case highlights the importance of careful history taking and consideration of neuroimaging to rule out central nervous system demyelinating diseases before start TNFAI therapy.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Pediatric AMPA Receptor Encephalitis (AMPARE): A Case Report and Literature Review (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2590;
He was given intravenous methylprednisolone (1 g/day over 5 days) and intravenous immunoglobulins (2 g/kg divided over 3 days) followed by steroid taper... Pediatric AMPARE is an extremely rare disorder that should be considered even with lack of clear limbic encephalitis.
- |||||||||| dexamethasone / Generic mfg.
69-Year-Old with Flaccid Paraplegia Immediately Post Epidural Steroid Injection (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2522;
This patient was treated with particulate forming methylprednisolone, which is associated with spinal cord stroke from accidental intra-arterial occlusion. Dexamethasone, a non-particulate forming steroid, is a readily available alternative, and if used in this patient, may have prevented a devastating disability.
- |||||||||| hydroxychloroquine / Generic mfg.
An Unusual Case of CLIPPERS ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2106;
MRI shows multiple punctate/curvilinear enhancing lesions in the brainstem and cerebellum, rarely in the spinal cord or supratentorially. Differential diagnoses include neurosarcoidosis, Behcet’s disease, vasculitis, lymphoma, chronic infections, glioma, and demyelinating disease.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Spinal Dural Arteriovenous Fistula: A diagnostic conundrum for neurologists ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2070;
In this case, clinical improvement with use of IV methylprednisolone and a nondiagnostic catheter angiogram posed a conundrum for the specialists involved. Though rare, spinal dural arteriovenous fistulas should be considered in patients with spinal cord edema and nonspecific symptoms.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Neuromelioidosis in the guise of a Demyelinating illness ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1944;
She was treated with IV methylprednisolone resulting in recovery without residual deficits... This case highlights the importance of considering Melioidosis in patients with atypical neurological presentations in endemic regions for better clinical outcome.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
MOG-ANTIBODY-ASSOCIATED DISEASE: an Argentinian hospital-based study ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1916;
Pediatric-onset patients had a different onset phenotype from adults. Most of the patients showed a good response to corticosteroid therapy for the treatment of relapses and some needed chronic immunosuppression.
- |||||||||| acyclovir / Generic mfg., meropenem / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Mild encephalitis/encephalopathy with reversible splenial lesion after COVID-19 vaccination ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1911;
Intravenous acyclovir and meropenem were administered under a possible diagnosis of aseptic meningitis but not effective. MERS should be considered in patients with neurological manifestation after COVID-19 vaccination, even though symptoms were mild and nonspecific.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Giant Cell Arteritis and Area Postrema Syndrome: Where Do We Stand? ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1832;
Nevertheless, area postrema syndrome does not figure among the possible clinical manifestations of the disease. Thus, this work highlights the possibility of this syndrome as a rare form of involvement of the central nervous system by giant cell arteritis.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Dilemma in Differentiating Posterior Reversible Encephalopathy Syndrome and Lupus Cerebritis in Systemic Lupus Erythematosus with Multi-Organ Involvement: A Case Report ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1781;
Lupus cerebritis and PRES have overlapping clinical features, radiographic findings, and CSF profiles.4-9 The finding of FLAIR hyperintense lesions in bilateral occipital and parietal areas on brain MRI, in the setting of uncontrolled hypertension and encephalopathy, is a classic radiographic pattern of PRES; however, other areas may also be involved radiographically.5,9 Microinfarctions and inflammatory CSF findings, such as pleocytosis and elevated protein, may be present in either condition.6 These overlapping features highlight a need for appropriate interpretation considering the clinical context. Our patient’s history of prior CNS lupus, encephalopathy in the setting of an active lupus flare and concurrent uncontrolled hypertension prompted initiation of treatment of both potential etiologies with subsequent improvement.
- |||||||||| acetazolamide / Generic mfg., cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
An Atypical Case of anti-GFAP Astrocytopathy ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1698;
Despite treatment with acetazolamide and bilateral optic nerve sheath fenestration, his vision did not improve. Here, we present previously undescribed manifestations of anti-GFAP astrocytopathy including rapid and profound visual loss associated with severe intracranial hypertension, thereby expanding the clinical spectrum of this rare disorder.
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
PT010 - Multidisciplinary Management of Advanced Non-Melanoma Skin Cancer (Location To Be Announced) - Mar 6, 2022 - Abstract #AAD2022AAD_1776;
Effective steroid therapy elevates motor cortex inhibition. Description Exhibiting Company: Regeneron/Sanofi Genzyme Theater 1: Booth 4471
- |||||||||| budesonide/formoterol (PT009) / AstraZeneca
PT009 - A Presentation by Sanofi Genzyme and Regeneron (Location To Be Announced) - Mar 6, 2022 - Abstract #AAD2022AAD_1765;
Description Exhibiting Company: Regeneron/Sanofi Genzyme Theater 1: Booth 4471 Description Exhibiting Company: Regeneron/Sanofi Genzyme Theater 1: Booth 4471
- |||||||||| triamcinolone acetonide / Generic mfg., albendazole / Generic mfg.
Biomarker, Retrospective data, Journal: Clinical Features and Prognostic Factors in Northern Chinese Patients with Peripheral Granuloma Type of Ocular Toxocariasis: A Retrospective Cohort Study. (Pubmed Central) - Mar 5, 2022
The combination therapy of vitreoretinal surgery, steroids, and albendazole therapy may reduce inflammation and recurrence of OT effectively. Abbreviations: BCVA: best-corrected visual acuity; BFGF: basic fibroblast growth factor; CFT: central foveal thickness; CI: confidence interval; ELISA: Enzyme-linked immunosorbent assay; ERM: epiretinal membrane; IOP: intraocular pressure; IQR: interquartile range; IL: interleukin; LFM: laser flare meter; MH: macular hole; OCT: optical coherence tomography; OR: odds ratio; OT: ocular toxocariasis; RD: retinal detachment; TA: triamcinolone acetonide; TCLA: Toxocara canis larva crude antigen; TGF: transforming growth factor; VCAM: vascular cell adhesion molecule; VEGF: vascular endothelial growth factor.
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Clinical, Journal, CAR T-Cell Therapy, PD(L)-1 Biomarker, IO biomarker: Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report. (Pubmed Central) - Mar 5, 2022
Due to atypical/overlapping pathological characteristics, it was initially misdiagnosed as extramedullary plasmacytoma and treated with two cycles of bortezomib, lenalidomide, and dexamethasone...The treatment was adjusted to etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab, and lenalidomide (R2-EPOCH), but no response was observed after three cycles of treatment and he developed hemophagocytic syndrome during treatment...The response assessment was partial for EBV-positive DLBCL, subsequent anti-CD19 chimeric antigen receptor-T (CAR-T) cell therapy resulted in complete remission including lumps, immunoglobulins, and negative EBV-DNA 1.5 months later. The present case study proved the possibility of PD-1 blockade in controlling EBV infection and associated hemophagocytic syndrome and offered an example of the combination of CAR-T therapy and PD-1 blockade for refractory EBV-positive DLBCL in clinic.
- |||||||||| dexamethasone / Generic mfg.
Journal: Zein-induced immune response and modulation by size, pore structure and drug-loading: application for sciatic nerve regeneration. (Pubmed Central) - Mar 5, 2022
Changing sphere sizes, pore structure and encapsulating dexamethasone could effectively modulate the zein-induced immune responses, especially the pore structure which also inhibited neutrophil recruitment and promoted macrophages polarizing towards M2 phenotype. Furthermore, the pore structures in zein nerve conduits was proved to alleviate the early inflammation and promote M2 macrophages polarization to accelerate nerve regeneration.
- |||||||||| dexamethasone / Generic mfg.
P2 data, Clinical Trial,Phase II, Journal: Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile. (Pubmed Central) - Mar 5, 2022
This prospective phase II trial provides a suggestion that the antiviral effects of CIP from early in the COVID-19 pandemic may delay progression to critical illness and death in specific patient populations. This study informs the optimal timing and potential population of use for CIP in COVID-19, particularly in settings without access to other interventions, or in planning for future coronavirus pandemics.
|
